Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

In June, Merck EVP Dean Li, M.D., Ph.D., told (PDF) investors that, with islatravir providing a “beachhead” in HIV, “advancing MK-8507 becomes very important.” Merck’s plan was to use MK ...

Merck was evaluating islatravir as a treatment for HIV-1 infection in combination with other antiretrovirals. With the FDA’s clinical hold in place, no new studies have been initiated on islatravir.

WASHINGTON (MarketWatch) -- The Food and Drug Administration said Friday that the benefits of a proposed HIV drug from Merck & Co. MRK, -0.44% outweigh "the currently identified risks." The FDA ...